Our results confirm the inhibitory effect of Vidofludimus on SARS-CoV-2 replication, and we extended this observation to BAY2402234, a potent DHODH inhibitor currently developed by Bayer as a treatment of acute myeloid leukemia [31]. The gene discussed is DHODH; the disease is acute myeloid leukemia.